Quantcast
Home > Quotes > CMRX
CMRX

Chimerix, Inc. Common Stock (CMRX) Quote & Summary Data

$3.36
*  
0.03
0.88%
Get CMRX Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading CMRX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 3.41 / $ 3.30
Share Volume
154,179
50 Day Avg. Daily Volume
176,874
Previous Close
$ 3.39
52 Week High / Low
$ 5.94 / $ 3.11
Market Cap
170,432,983
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
154,179
50 Day Avg. Daily Volume:
176,874

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.55

Trading Range

The current last sale of $3.36 is 8.04% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.41 $ 5.94
 Low: $ 3.30 $ 3.11

Company Description (as filed with the SEC)

Chimerix, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. We were founded in 2000 based on the promise of our proprietary lipid conjugate technology to unlock the potential of some of the most broad-spectrum antivirals by enhancing their antiviral activity and safety profiles in convenient dosing regimens. Our lead compound, brincidofovir (BCV), is in development as an oral and intravenous (IV) formulation for the prevention and treatment of DNA viruses, including smallpox, adenovirus (AdV), and the human herpesviruses. We are also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, we have an active discovery program focusing on viral targets for which limited or no therapies are currently available.  ... More ...  


Risk Grade

Where does CMRX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.40
Open Date:
Dec. 13, 2018
Close Price:
$ 3.36
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info